Benserazide is an aromatic L-amino-acid decarboxylase inhibitor that has been co-administered with levodopa (L-Dopa) for decades to boost dopamine levels in the brain in the treatment of Parkinson disease. This evidence concerns the gene DDC and Parkinson disease.